Propanc's annual operating loss shrank by roughly the price of a small biotech acquisition, from $57.3 million to $18.2 million. The other number is the one tied to the bank account: operating cash outflow rose from $405,168 to $5.7 million in the twelve months ended June 30, 2026.
The latest 10-K also shows a change in the kind of loss being reported. Net loss narrowed to $18.9 million from $58.9 million, while diluted shares jumped from 158,700 to 1.1 million. The company also recorded $8.5 million of stock compensation, up from $4.6 million, a non-cash expense that still matters because it arrives alongside more shares.
Management says the year carried a heavier public-company bill. Propanc listed on the Nasdaq Capital Market, and the costs attached to that move pushed administration expenses higher.
"The overall increase in administration expenses during fiscal year 2026 was primarily attributable to increased costs associated with the Company’s listing on the Nasdaq Capital Market, including higher regulatory and compliance costs, insurance expenses, and other public company-related expenditures."
Propanc Biopharma, Form 10-K, Sept. 25, 2026
That explains the disclosed increase in administration costs, not the full movement in cash flow. The 10-K does not give a single cause for the swing from a roughly $400,000 operating cash outflow to $5.7 million.
The business is still measured in clinical milestones rather than sales. Propanc's timeline puts its Phase Ib clinical study protocol work in late 2026, with trial-site preparation in early 2027 and the first patient visit in April 2027. The company's own estimate for a Phase IIa proof-of-concept milestone is three to four years, subject to regulatory approval and research results.
"We anticipate reaching the Phase Iia proof of concept milestone in approximately three to four years, subject to regulatory approval in US, Europe and Australia, and the results from our R&D and licensing activities."
Propanc Biopharma, Form 10-K, Sept. 25, 2026
The timeline puts the annual accounting improvement in perspective. Research and development spending rose to $625,500 from $223,700, but that remains a small outlay next to the year's $5.7 million operating cash use. The filing shows a company spending more on development while the key clinical milestone remains years away.
There is a possible offset in Australia. Propanc says it may receive a refund of up to 43.5% of qualified research and development costs, subject to approval. That is a potential source of liquidity, not cash already received, and the filing does not quantify its effect on the year just reported.
The share price adds another layer. PPCB closed at $0.64 on Sept. 25, up 9.8% that day, after a 12-month return of negative 71.4% and a six-month return of positive 367.3%. A volatile quote can coexist with a filing focused on cash use, share count, and clinical progress.
For the next reported period, the number to compare is the $5.7 million operating cash outflow, alongside whether the diluted share count remains near 1.1 million as Propanc advances toward the April 2027 first-patient milestone.
Source: Propanc Biopharma's Form 10-K filed Sept. 25, 2026.